AI-Powered Pharmacovigilance for Post-Market Drug Safety Monitoring

Drug safety signals can appear in social media conversations and other non-medical reports, but their volume and unstructured format make them difficult to evaluate using conventional pharmacovigilance processes.

CapeStart developed an AI-powered solution that identifies potential adverse drug reactions, filters causal mentions, supports medical coding, and generates structured safety narratives. Extracted data is converted into customized pharmacovigilance reports, including CIOMS and E2B formats, to support faster review and regulatory reporting.

Download the case study to explore how AI can help pharmacovigilance teams turn unstructured consumer reports into actionable drug safety insights.